Immunotherapy Markers

The present invention relates to the identification and use of neutrophil defensin 1, neutrophil defensin 2 and/or neutrophil defensin 3 as markers indicative for the response of a subject to immunotherapy as anti-cancer treatment. The markers are particularly useful in predicting response of a subject to immunotherapy with PD-1 or PD-L1 antagonists in the treatment of cancer. PD-1 and PD-L1 antagonists are typically used as immunotherapy in the treatment of several types of cancer, including melanoma, non-small cell lung cancer (NSCLC), and squamous cell carcinoma.

Octrooi-publicatienummer: EP3792632

Jaar aanvraag: 2021

Jaar toekenning: 2022

Jaar van publicatie: 2021

Status: Aangevraagd

Technologiedomeinen: Analyse van biologische materialen

Gevalideerd voor IOF-sleutel: Ja

Toegewezen aan: Associatie Universiteit & Hogescholen Antwerpen